HOME >> BIOLOGY >> NEWS
Unusual three-drug combo inhibits growth of aggressive tumors

An experimental anti-cancer regimen combined a diuretic, a Parkinson's disease medication and a drug ordinarily used to reverse the effect of sedatives. The unusual mixture inhibited the growth of aggressive prostate tumors in laboratory mice in research conducted at Washington University School of Medicine in St. Louis.

Although their drug choices may seem capricious, the researchers weren't randomly pulling drugs from their shelves. They made their discovery using sophisticated methods for delving into the unique metabolism of cancer cells and then choosing compounds likely to interfere with their growth.

"This study, led by Joseph Ippolito, a very talented M.D./Ph.D. student, demonstrates the importance of looking at tumor metabolism," says senior author Jeffrey I. Gordon, M.D, director of the Center for Genome Sciences at the School of Medicine. "Using a broad array of technology, we've obtained a view of the tumor cells' metabolome (the set of small-molecule metabolites found within cells) and revealed aspects that were not expected and could be exploited."

The findings, published in a recent article in the Proceedings of the National Academy of Sciences, expand upon earlier work by the research group, which demonstrated that aggressive types of neuroendocrine tumors - seen in some types of lung, thyroid and prostate cancers - produce high amounts of a chemical called GABA, a neurotransmitter.

Because of the abundance of GABA in these tumors, the authors previously proposed that the chemical could potentially serve as a marker for poor-prognosis neuroendocrine tumors. But the latest findings also show that the techniques used to decipher the biochemistry of the tumors can effectively be applied to seek drugs that will affect tumor metabolism.

The techniques link DNA microarray technology - which can pinpoint highly active genes in the tumors - to precise measurements of abundant metabolites and their potential byp
'"/>

Contact: Gwen Ericson
ericsong@wustl.edu
314-286-0141
Washington University School of Medicine
7-Sep-2006


Page: 1 2 3

Related biology news :

1. Unusual data shed new light on brain and inhibiting behavior
2. Unusual mechanism keeps repair protein accurate
3. Unusual RNAs linked to chronic leukemia, may help treat it
4. Unusual antibiotics show promise against deadly superbugs
5. Unusual reproductive behavior of odd ants surprises scientists
6. Dramatic results from combo therapy surprises Krabb-disease researchers
7. Drug combo may reduce protease inhibitor-related hardening of the arteries
8. AVN944 inhibits IMPDH and induces apoptosis-related biomarkers in patients with hematologic cancers
9. Gene therapy inhibits epilepsy in animals
10. Antibiotic inhibits cancer gene activity
11. Activation of microRNA inhibits cancer gene in human cancer cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/21/2020)... ... 21, 2020 , ... Agility Orthopedics, home to dedicated specialists ... is pleased to announce a partnership with Dallas-based Simple Interact to further enhance ... area, Agility Orthopedics is focused on speeding up patient workflows to enhance patient ...
(Date:5/14/2020)... ... May 12, 2020 , ... ... Science Manufacturers accurately and easily project contracted liabilities with payers, providers and ... by projecting discounts/rebates to Commercial and Government entities, Copay and Patient Assistance ...
(Date:5/14/2020)... ALPHARETTA, Ga. (PRWEB) , ... May 14, 2020 ... ... ), a job board for medical sales representatives, found the 2019 average medical ... encouraging 2020 findings risk being shadowed by uncertainties amid the COVID-19 global crisis. ...
Breaking Biology News(10 mins):
(Date:5/15/2020)... ... May 14, 2020 , ... Children ... open heart surgeries before becoming adults. The reason: there are no heart ... critical unmet need, the Department of Defense has awarded Draper, Boston Children’s Hospital ...
(Date:5/14/2020)... ... May 12, 2020 , ... DuPont ... new distribution partner for all personal care ingredients in Russia and Belarus. Beginning ... DuPont preservative portfolio for personal care. , The GENENCARE®OSMS product line ...
(Date:5/14/2020)... ... May 13, 2020 , ... Early stages of drug ... or no information on the drug’s mechanism of action (MOA). Gene expression profiling ... measuring the activity of molecular pathways. This information can complement phenotypic readouts and ...
(Date:5/5/2020)... ... , ... ProductLife Group has marked the next phase in its ... 13 years at Altran, where he was Group VP of Life Sciences and Head ... Pharmacist, Xavier was involved in his early career in the development of new medical ...
Breaking Biology Technology:
Cached News: